After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
After its historic first green light, the ‘temporary approval’ issued by the UK on 2 December, Pfizer/BioNTech’s coronavirus vaccine is tipped to be the leader in a market worth $38.5bn next year.
A newly revised forecast by analysts at Bernstein expects there to be five main players, with Pfizer now expected to...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
